Stage ? oligometastatic esophageal squamous cell carcinoma
Conditions
Interventions
A:chemoradiotherapy
Sponsors
Cancer Hospital of Sichuan province
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. voluntary and signed written informed consent; 2. aged 18 to 75 years, sex not limited; 3. pathology or cytology in the diagnosis of esophageal squamous cell carcinoma; 4. clinic stage IV (distant metastases number = 5distant organ metastases number = 3); 5. NO previous treatment(who had not previously been treated by radiotherapy,chemotherapy or molecular targeted therapy); 6. primary tumor can be measured; 7. Karnofsky score >70; 8. survival is expected to exceed 3 months; 9. reproductive age women should ensure that before entering the study period contraception; 10. HB =100 g/L, WBC =4 ×10^9/L, platelet = 100 ×10^9/L; 11. liver function: the upper limit of normal value of ALT, AST 50%, DLCO (lung dispersion function) the percentage of measured value of estimated value >80%; 14. patients have good compliance to treatment and follow-up of acceptance.
Exclusion criteria
Exclusion criteria: 1. Do not meet the inclusion criteria for patients with pathologic type,stage and survival condition; 2. esophageal perforation (esophageal tracheal fistula or patients who may have esophageal tracheal fistulas); 3. Other malignancies but exception of curative skin cancer(non-melanoma), cervical carcinoma in situ , bladder epithelial cancer in situ or malignant disease curatively more than 5 years; 4. Original serious heart disease, including: congestive heart failure, high-risk sexual beyond the control of the rhythm of the heart failure, unstable angina, half a year of myocardial infarction, severe valvular heart disease, and resistant hypertension; 5. There is serious allergic or idiosyncratic; 6. Refused or not signed the informed consent to participate in trials; 7. Patients with uncontrollable nerve, mental illness, or mental disorders, depending on the sex, cannot cooperation and adverse response for descriptive treatment; 8. The researchers do not think participating in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tumor size; | — |
Countries
China
Contacts
Public ContactLi Tao
Outcome results
None listed